tirzepatide and bone loss The promise of tirzepatide: A narrative review of metabolic benefits Tirzepatide for Medical Weight Loss

Brand-name drugs under patent protection (Mounjaro patent runs through 2036) dont have generic competition forcing prices down, and the manufacturer controls all rebate structures

With existing FDA approval and established safety profiles, this class of medications presents a promising opportunity for repurposing in addiction treatment

Clinical trials show sustained benefits over 72 weeks with continued GLP-1 and GIP receptor activation, though real-world treatment varies significantly based on patient-specific factors

The use of sulphonylureas, glinides or thiazolidinediones to manage type 2 diabetes is associated with a typical weight gain of 25 kg [52], but a randomised controlled comparison of acarbose and glibenclamide as monotherapy in 96 patients with diabetes found no weight changes associated with acarbose therapy [32]